hepatitis

liver
Biotech

Bausch Health bags phase 3-ready liver prospect in $63M buyout

Bausch Health has struck a deal to buy Durect, landing a phase 3-ready liver disease candidate that the companies believe has blockbuster potential.
Nick Paul Taylor Jul 29, 2025 9:35am
green light shining in night

Kezar sees hepatitis hold lifted, mulls restarting lupus program

Jul 16, 2025 8:47am
Signage for the Department of Health and Human Services HHS headquarters is seen on April 02 2025 in Washington DC
Favicon Fierce Healthcare

Judge sides with states, blocking HHS reorg and mass layoffs

Jul 1, 2025 3:30pm
plan B fail reroute road path trail miss

Surrozen drops sole clinical-stage drug over weak hepatitis data

Mar 24, 2025 10:50am
FDA stop sign

FDA hits Kezar's zetomipzomib with 2nd clinical hold in 2 months

Nov 13, 2024 5:22am
cancer target detection radiopharma radio

Kezar drops solid tumor yet to prove its worth in phase 1 trial

Aug 14, 2024 5:09am